Abbott Says Decision To Discontinue Cylert Stems From Demand, Not Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Significant decline in pemoline sales is reason behind the ADHD agent's discontinuation, not liver safety issues raised in a Public Citizen petition to FDA, Abbott says. Public Citizen seeks withdrawal of Cylert and generics; the petition references two analyses of pemoline conducted by FDA drug safety officer Graham.
You may also be interested in...
FDA Pulls Abbott’s Cylert From Market Due To Liver Toxicity
The ADHD drug will no longer be available after current supplies of pemoline generics are exhausted. Abbott stopped marketing the drug in May, citing low sales.
FDA Pulls Abbott’s Cylert From Market Due To Liver Toxicity
The ADHD drug will no longer be available after current supplies of pemoline generics are exhausted. Abbott stopped marketing the drug in May, citing low sales.
Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says
Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.